TMC2: A Drug Target / Disease Biomarker (G117532)

Target Name: TMC2

NCBI ID: G117532

TMC2

TMC2: A Drug Target / Disease Biomarker

TMC2, also known as 2-methylpropionitrile, is a drug target (or biomarker) that has been shown to have potential in treating various neurological disorders. TMC2 is a small molecule that is derived from the amino acid leucine. It is found in the brain and is known to play a role in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.

One of the main reasons for the potential of TMC2 as a drug target is its unique structure. TMC2 is a fatty acid amide, which means that it has a hydrophobic (water-repelling) tail and a hydrophilic (water-attracting) head. This structure allows it to interact with fatty acids in the brain, which are known to be important for the development of certain neurological disorders.

In addition to its unique structure, TMC2 has also been shown to interact with certain proteins that are involved in the development of neurological disorders. For example, studies have shown that TMC2 can interact with the protein called TrkB, which is involved in the development of neurodegenerative disorders. This interaction may be important for understanding how TMC2 contributes to the development and progression of these disorders.

Another reason for the potential of TMC2 as a drug target is its ability to cross the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the blood and helps to protect the brain from harmful substances. However, this barrier can also prevent the delivery of drugs to the brain, which can make it difficult to treat certain neurological disorders. TMC2 has been shown to be able to cross the blood-brain barrier and deliver it to the brain, which may make it an attractive drug candidate for the treatment of certain neurological disorders.

In addition to its potential as a drug target, TMC2 has also been shown to have potential as a biomarker. Studies have shown that TMC2 levels are decreased in the brains of individuals with Alzheimer's disease and other neurological disorders. This suggests that TMC2 may be a useful biomarker for the diagnosis and progression of these disorders. In addition, TMC2 levels have also been shown to be decreased in the brains of individuals with depression, which may make it an attractive biomarker for the treatment of this disorder.

Overall, TMC2 is a drug target (or biomarker) that has potential in treating various neurological disorders. Its unique structure, ability to interact with certain proteins, and ability to cross the blood-brain barrier make it an attractive candidate for the development and treatment of these disorders. Further research is needed to fully understand the potential of TMC2 as a drug and to develop safe and effective treatments for the treatment of neurological disorders.

Protein Name: Transmembrane Channel Like 2

Functions: Probable ion channel required for the normal function of cochlear hair cells (PubMed:11850618). Component of the hair cell's mechanotransduction (MET) machinery. Involved in mechanosensitive responses of the hair cells (By similarity)

The "TMC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets